GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Other Income (Expense)

Astellas Pharma (Astellas Pharma) Other Income (Expense) : $62 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Other Income (Expense)?

Astellas Pharma's other income expense for the Astellas Pharma's pretax income for the three months ended in Dec. 2023 was $1 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was $62 Mil.


Astellas Pharma Other Income (Expense) Historical Data

The historical data trend for Astellas Pharma's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Other Income (Expense) Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.65 -15.43 4.40 208.50 11.02

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.75 -0.79 5.23 57.09 0.66

Astellas Pharma Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (OTCPK:ALPMY) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (Astellas Pharma) Headlines

From GuruFocus

Astellas to Acquire Propella Therapeutics

By PRNewswire 11-16-2023